- Home
- EDF vs TLSI Comparison
EDF vs TLSI Comparison
Compare EDF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- TLSI
- Stock Information
- Founded
- EDF 2010
- TLSI 2010
- Country
- EDF United States
- TLSI United States
- Employees
- EDF N/A
- TLSI N/A
- Industry
- EDF Investment Managers
- TLSI Medical Specialities
- Sector
- EDF Finance
- TLSI Health Care
- Exchange
- EDF Nasdaq
- TLSI Nasdaq
- Market Cap
- EDF 148.8M
- TLSI 160.4M
- IPO Year
- EDF N/A
- TLSI N/A
- Fundamental
- Price
- EDF $4.93
- TLSI $5.02
- Analyst Decision
- EDF
- TLSI Strong Buy
- Analyst Count
- EDF 0
- TLSI 6
- Target Price
- EDF N/A
- TLSI $11.75
- AVG Volume (30 Days)
- EDF 160.6K
- TLSI 33.4K
- Earning Date
- EDF 01-01-0001
- TLSI 05-14-2025
- Dividend Yield
- EDF 13.14%
- TLSI N/A
- EPS Growth
- EDF N/A
- TLSI N/A
- EPS
- EDF N/A
- TLSI N/A
- Revenue
- EDF N/A
- TLSI $29,431,000.00
- Revenue This Year
- EDF N/A
- TLSI $56.00
- Revenue Next Year
- EDF N/A
- TLSI $52.17
- P/E Ratio
- EDF N/A
- TLSI N/A
- Revenue Growth
- EDF N/A
- TLSI 58.99
- 52 Week Low
- EDF $3.51
- TLSI $3.50
- 52 Week High
- EDF $5.50
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- EDF 52.63
- TLSI 34.87
- Support Level
- EDF $4.81
- TLSI $4.66
- Resistance Level
- EDF $4.92
- TLSI $5.40
- Average True Range (ATR)
- EDF 0.10
- TLSI 0.37
- MACD
- EDF 0.02
- TLSI -0.06
- Stochastic Oscillator
- EDF 64.63
- TLSI 29.51
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.